{"filing":{"accession_number":"0000899923-26-000070","cik":"0000899923","ticker":"MYGN","company_name":"MYRIAD GENETICS INC","form":"8-K","filing_date":"2026-07-30","report_date":"2026-07-30","primary_document":"mygn-20260730.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/899923/000089992326000070/mygn-20260730.htm"},"events":[{"id":22534,"run_id":20388,"accession_number":"0000899923-26-000070","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"Myriad Genetics disclosed its second quarter 2026 financial results on July 30, 2026, via Item 2.02 with the earnings release attached as Exhibit 99.1. The disclosure includes revenue of $190.7 million (down 11% YoY), operating loss of $38.9 million, revised full-year 2026 guidance, and suspension of Adjusted EBITDA guidance. This is a standard quarterly earnings announcement material to investors assessing the company's financial performance and outlook.","company_name":"MYRIAD GENETICS INC","ticker":"MYGN","filing_date":"2026-07-30","form":"8-K","submitted_at":null,"items":[{"id":22506,"accession_number":"0000899923-26-000070","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Myriad Genetics disclosed its second quarter 2026 financial results on July 30, 2026, via Item 2.02 with the earnings release attached as Exhibit 99.1. The disclosure includes revenue of $190.7 million (down 11% YoY), operating loss of $38.9 million, revised full-year 2026 guidance, and suspension of Adjusted EBITDA guidance. This is a standard quarterly earnings announcement material to investors assessing the company's financial performance and outlook.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-01T02:17:29.312869+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":22506,"accession_number":"0000899923-26-000070","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Myriad Genetics disclosed its second quarter 2026 financial results on July 30, 2026, via Item 2.02 with the earnings release attached as Exhibit 99.1. The disclosure includes revenue of $190.7 million (down 11% YoY), operating loss of $38.9 million, revised full-year 2026 guidance, and suspension of Adjusted EBITDA guidance. This is a standard quarterly earnings announcement material to investors assessing the company's financial performance and outlook.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-01T02:17:29.312869+00:00","company_name":"MYRIAD GENETICS INC","ticker":"MYGN","filing_date":"2026-07-30"}]}